By InvitationNot Applicable

FAST (Focused Abbreviated Screening Technique)-MRI Study

United States820 participantsStarted 2020-08-17

Plain-language summary

The purpose of this study is to compare the diagnostic value of a reconstructed abbreviated Magnetic Resonance Imaging (MRI) from a full clinical exam, compared to ultrasound (US) for screening of liver cancer. Blood markers will be evaluated to determine their correlation to imaging. This study will help to determine whether abbreviated MRI is superior to ultrasound for diagnosis of liver cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria * Liver cirrhosis of any etiology. * 18 years of age and older. * Enrolled in screening/surveillance program for HCC. * Clinically indicated imaging-based screening for HCC. * Willing and able to complete all study procedures within specified time windows. * Patient is able to give informed consent for this study. Exclusion Criteria * Contra-indications to MRI. * Age less than 18 years. * Patients with chronic renal failure or inability to tolerate contrast. * Inability to undergo MRI due to lack of insurance coverage. * Prior negative screening exam less than 5 months prior to enrollment. * Prior hepatic resection. * Post liver transplantation. * Previously treated HCC or other liver neoplasm. * Any other condition or factor that in judgment of study investigator may interfere with study completion.

What they're measuring

Presence of HCC

Timeframe: Within 6 months after initial index imaging (MRI & US)

Trial details

NCT IDNCT04539717

SponsorIcahn School of Medicine at Mount Sinai

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-05-31

View on ClinicalTrials.gov More Hepatocellular Carcinoma (HCC) trials